GlassScriptPhysician profile
Amy Goodrich
NPI 1649224916
$26,659.51
in general payments reported to CMS, 2019-2025
20 companies · $2,703 in 2025
The $2,703 reported for 2025 was more than what 97% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $7,384 · 2022: $9,625 · 2023: $4,525 · 2024: $2,422 · 2025: $2,703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,921 · Food and Beverage: $729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,921.25 |
| Food and Beverage | $729.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,717.13 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $3,499.87 | 2021-2024 | Calquence, Imfinzi |
| Genzyme Corporation | $3,178.00 | 2021-2022 | |
| Beigene USA, INC. | $2,445.32 | 2021-2024 | Brukinsa |
| Epizyme, INC. | $1,750.00 | 2022 | |
| Eli Lilly and Company | $1,650.00 | 2025 | Jaypirca |
| Fresenius Kabi USA, LLC | $1,479.99 | 2021-2023 | Stimufend |
| Janssen Scientific Affairs, LLC | $1,380.00 | 2022 | |
| Incyte Corporation | $1,050.00 | 2024 | |
| Beigene, LTD. | $1,040.00 | 2021 | |
| Genentech USA, INC. | $900.00 | 2022 | |
| Genentech, INC. | $900.00 | 2021 | |
| Genmab U.S., INC. | $796.25 | 2025 | Epkinly |
| Pharmacyclics LLC, An Abbvie Company | $675.00 | 2021 | |
| Seagen INC. | $580.00 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $242.67 | 2024-2025 | Carvykti, Rybrevant, Darzalex |
| Adc Therapeutics America, INC. | $125.30 | 2025 | |
| Pfizer INC. | $118.86 | 2024 | |
| Daiichi Sankyo INC. | $117.78 | 2024 | Enhertu |
| Celgene Corporation | $13.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Goodrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.